Tetracycline-Responsive CAR Expression System
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CAR expression systems in immunotherapies lack specificity and control, leading to broad expression across different cell types and stages of differentiation, which can be detrimental and inefficient.
Innovation Solution
A tetracycline-responsive expression system comprising a first expression cassette with a cell type-specific promoter for a tetracycline-responsive transactivator and a second cassette for a chimeric antigen receptor, allowing for inducible and specific expression in targeted immunotherapeutic cells like CAR-T or CAR-NK cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a constitutive promoter is used to drive CAR expression, then CAR expression is continuous and strong, but expression occurs in all cell types including non-target cells
Solution Approach 1:
The patent applies cell type-specific promoters (e.g., CD8 promoter for T cells, CD56 promoter for NK cells) to ensure CAR expression occurs only in the intended target cell type. This localizes the harmful effect by preventing CAR expression in non-target cells while maintaining expression in the specific therapeutic cell population, thereby reducing off-target effects while preserving therapeutic reliability.
Solution Approach 2:
The patent employs inducible promoters (tetracycline-responsive promoters) that allow dynamic control of CAR expression. The system transitions from a static constitutive expression model to a dynamic controllable system where CAR expression can be activated only when needed and can be modulated by external agents, providing both temporal and conditional control to prevent off-target effects.
2Reliability
If a constitutive promoter is used, then CAR expression is strong and continuous, but expression occurs at all stages of differentiation including immature cells
Solution Approach 1:
The patent uses stage-specific promoters (e.g., CD3D promoter for mature T cells, CD94 promoter for NK cells) to restrict CAR expression to specific differentiation stages. This ensures that CAR expression is localized to the appropriate cell maturity level, preventing expression in immature cells that may not be the intended therapeutic target, thereby improving cell type specificity while maintaining expression reliability in the correct population.
3Adaptability or versatility
If broad promoters are used, then CAR expression is achieved in multiple cell types, but this reduces therapeutic specificity and increases toxicity
Solution Approach 1:
The patent replaces broad promoters with cell type-specific promoters that are active only in the intended therapeutic cell type. This localized approach ensures that CAR expression and subsequent therapeutic activity occur only where needed, preventing toxic effects in other cell types while maintaining the ability to treat the specific disease indication, thereby reducing toxicity while preserving therapeutic adaptability.
Solution Approach 2:
The patent employs inducible promoter systems that allow dynamic control of CAR expression timing and level. This enables the system to adapt expression to the specific therapeutic need, activating CAR expression only when treatment is required and controlling the magnitude of expression to achieve therapeutic effect without causing excessive toxicity, thus balancing adaptability with harm reduction.
Data Source
AI summary
Aspects of this disclosure provide nucleic acid constructs A nucleic acid construct, comprising a first expression cassette comprising a nucleic acid encoding a tetracycline-responsive transactivator under the control of a cell type-specific promoter; and a second expression cassette comprising a nucleic acid encoding a transgene, for example, a chimeric antigen receptor (CAR), under the control of a tetracycline-responsive promoter.